Recent SPECT (177Lu-PCTA-cetuximab) and PET (64Cu-PCTA-cetuximab) imaging indicated the suitability of these agents to be used for specific targeting of tumours that express high levels of EGFR and, furthermore, the potential for radioimmunotherapy using the same radionuclides in cetuximab-resistant tumours [35]. This evidence concerns the gene EGFR and neoplasm.